All In Biotech

Drug Trial Radar · NCT06510816

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 659 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

659

Actual

Start

Jul 30, 2024

Primary completion

Jul 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Annexon, Inc.Industry
Sponsor type
Industry
First posted
Jul 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Conditions

  • Geographic Atrophy

Interventions

  • VonaprumentDrug

    Form: solution for injection; Route of Administration: IVT injection

  • Sham AdministrationOther

    Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive VisitsTime frame: Baseline through Month 15
  2. Proportion of Participants Experiencing a BCVA ≥15-letter Loss from Baseline Through Month 24 as Assessed by the ETDRS Chart at Any Two Consecutive VisitsTime frame: Baseline through Month 24

Locations

132 sites in 14 countries. Site status is shown where the registry gives one.

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retinal Consultants of Orange County Clinical Research Institute Inc

    Fullerton, California

  • Global Research Management

    Glendale, California

  • Retina Consultants Medical Group

    Modesto, California

  • Northern California Retina Vitreous Associates Medical Group, Inc.

    Mountain View, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Macula Retina Vitreous Research Institute

    Torrance, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Retina Consultants of Southern Colorado PC

    Colorado Springs, Colorado

  • RSC Research, LLC

    Denver, Colorado

  • Rand Eye Institute

    Deerfield Beach, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Group of Florida

    Sarasota, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • Retina Associates of Florida

    Tampa, Florida

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Retina Associates Ltd

    Elmhurst, Illinois

  • University Retina

    Oak Forest, Illinois

  • Springfield Clinic LLP

    Springfield, Illinois

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Maine Eye Center

    Portland, Maine

  • Retina Group of Washington

    Chevy Chase, Maryland

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Retina Research Institute at New England Retina Consultants

    Springfield, Massachusetts

  • Retina Consultants of Minnesota

    Saint Louis Park, Minnesota

  • Sierra Eye Associates

    Reno, Nevada

  • Envision Ocular, LLC

    Bloomfield, New Jersey

  • Mid Atlantic Retina New Jersey

    Cherry Hill, New Jersey

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico

  • Long Island Vitreoretinal Consultants

    Hauppauge, New York

  • Asheville Eye Associates - Retina Division

    Asheville, North Carolina

  • North Carolina Retina Associates

    Cary, North Carolina

  • North Carolina Retina Associates

    Wake Forest, North Carolina

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.